Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
type
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

78512

	registered interest
	date	16/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Osteoarthritis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many people have suffered complications following knee and hip operations related to osteoarthritis in the last five years.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	type	WrittenParliamentaryQuestion
	uin	206190
	answer	answer is ministerial correction date of answer 22/07/2014 answer text <p>This information is not available. Although some information on post-operative complications experienced by osteoporosis patients following surgery of the hip and knee is available via the Health and Social Care Information Centre’s Patient Reported Outcome Measures (PROMs) data collection, this only covers hip and knee replacement, and not the full range of surgical interventions. In addition to this, as PROMs is a voluntary reporting system the data published does not reflect the total number of osteoporosis patients having complications for all hip and knee replacements. More information on PROMS data can be found at the following link:</p><p> </p><p><a href="http://www.hscic.gov.uk/proms" target="_blank">www.hscic.gov.uk/proms</a></p><p><strong> </strong></p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 22/07/2014 13:39:02 answering member 1439 label Biography information for Norman Lamb
	tabling member	4034 label Biography information for Yvonne Fovargue

90496

	registered interest
	date	03/09/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what the next step is in the commissioning of a specialised service after a positive recommendation by the Prescribed Specialised Services Advisory Group (PSSAG); whether services recommended for commissioning by PSSAG in September 2014 will be funded from April 2015; when the PSSAG recommendations on the application for a specialised service for Alpha-1 Antitrypsin Deficiency will be published; and if he will make a statement.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	type	WrittenParliamentaryQuestion
	uin	208035
	answer	answer is ministerial correction date of answer 10/09/2014 answer text <p> </p><p>The Prescribed Specialised Services Advisory Group (PSSAG) is a Department of Health expert committee which provides advice to Ministers on which services should be prescribed in regulations for national commissioning by the NHS Commissioning Board (NHS England).</p><p> </p><p> </p><p> </p><p>PSSAG makes recommendations to Ministers, who are obliged under section 3B of the National Health Service Act 2006 to take appropriate advice and to consult with NHS England before making regulations to prescribe particular services as specialised services for NHS England commissioning. Decisions on the timing of any changes to commissioning responsibilities will take account of advice from PSSAG and any consultation response from NHS England.</p><p> </p><p> </p><p> </p><p>Where a service is prescribed for national commissioning, NHS England becomes responsible for making decisions on the commissioning of that service, including funding of specific interventions as part of that service. We understand from NHS England that where it becomes the responsible commissioner for a service, it considers the funding priority of the service through its Clinical Priorities Advisory Group.</p><p> </p><p> </p><p> </p><p>We understand the Alpha 1 Alliance has worked with NHS England and the Specialised Respiratory Clinical Reference Group to develop a proposal for the national commissioning of services for patients with alpha 1-antitrypsin deficiency, which will be put to PSSAG for consideration at its next meeting on 30 September. A report containing PSSAG’s recommendations will be published once Ministers have made decisions on any associated changes.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 10/09/2014 12:18:26 answering member 3918 label Biography information for Jane Ellison
	tabling member	4034 label Biography information for Yvonne Fovargue

147552

	registered interest
	date	10/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Breast Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he is taking to ensure that (a) NHS England continues to routinely assess the quality and safety of local breast cancer multi-disciplinary teams and network groups as part of the National Cancer Peer Review programme and (b) this information is made available to patients through the My Cancer Treatment website.
	tabling member constituency	Bolton South East
	tabling member printed	Yasmin Qureshi
	type	WrittenParliamentaryQuestion
	uin	213933
	answer	answer is ministerial correction date of answer 20/11/2014 answer text <p>NHS England is currently reviewing the National Cancer Peer Review Programme with a view to considering how its success might be extended into other new areas of specialised commissioning. Further details, including how the public can access information on the quality of clinical services, will be available following the completion of the review.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 20/11/2014 16:45:59 answering member 3918 label Biography information for Jane Ellison
	tabling member	3924 label Biography information for Yasmin Qureshi

147553

	registered interest
	date	10/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he is taking to ensure routine access to tamoxifen and raloxifene for the indication of chemoprevention in the UK.
	tabling member constituency	Bolton South East
	tabling member printed	Yasmin Qureshi
	type	WrittenParliamentaryQuestion
	uin	213936
	answer	answer is ministerial correction date of answer 19/11/2014 answer text <p>In June 2013 the National Institute for Health and Care Excellence (NICE) issued an updated clinical guideline on familial breast cancer which includes recommendations on the use of tamoxifen and raloxifene outside their licensed indications for the prevention of cancer in specific groups of women at high and moderate risk of breast cancer.</p><p> </p><p> </p><p> </p><p>NICE’s clinical guidelines represent best practice and we expect commissioners to take their recommendations into account when designing services and making commissioning decisions for their healthcare population.</p><p> </p><p><strong> </strong></p><p> </p><p>Information on the number of women treated with tamoxifen and raloxifene for the treatment or prevention of breast cancer is not collected centrally.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 213934 question first answered 19/11/2014 15:55:55 answering member 4020 label Biography information for George Freeman
	tabling member	3924 label Biography information for Yasmin Qureshi

147554

	registered interest
	date	10/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what proportion of women who are eligible for tamoxifen and raloxifene are offered this treatment.
	tabling member constituency	Bolton South East
	tabling member printed	Yasmin Qureshi
	type	WrittenParliamentaryQuestion
	uin	213934
	answer	answer is ministerial correction date of answer 19/11/2014 answer text <p>In June 2013 the National Institute for Health and Care Excellence (NICE) issued an updated clinical guideline on familial breast cancer which includes recommendations on the use of tamoxifen and raloxifene outside their licensed indications for the prevention of cancer in specific groups of women at high and moderate risk of breast cancer.</p><p> </p><p> </p><p> </p><p>NICE’s clinical guidelines represent best practice and we expect commissioners to take their recommendations into account when designing services and making commissioning decisions for their healthcare population.</p><p> </p><p><strong> </strong></p><p> </p><p>Information on the number of women treated with tamoxifen and raloxifene for the treatment or prevention of breast cancer is not collected centrally.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 213936 question first answered 19/11/2014 15:55:55 answering member 4020 label Biography information for George Freeman
	tabling member	3924 label Biography information for Yasmin Qureshi

147559

	registered interest
	date	10/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will take steps to ensure that clinically-proven, cost-effective drugs are made routinely available to all when they are shown to be of use in a new indication but are off-patent.
	tabling member constituency	Bolton South East
	tabling member printed	Yasmin Qureshi
	type	WrittenParliamentaryQuestion
	uin	214030
	answer	answer is ministerial correction date of answer 19/11/2014 answer text <p>We support appropriate use of off-patent medicines in areas where the evidence suggests that they can deliver patient benefit. Doctors can already prescribe a drug outside its licensed indications where they judge it to be the most clinically appropriate treatment for an individual patient. Medicines are routinely prescribed legally, safely and appropriately outside their licensed indications to large numbers of National Health Service patients.</p><p> </p><p> </p><p> </p><p>We are in the process of setting up a round-table discussion with key stakeholders, NHS England and the National Institute for Health and Care Excellence to review the evidence and explore opportunities to work together to better support appropriate use of these medicines.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 19/11/2014 16:02:12 answering member 4020 label Biography information for George Freeman
	tabling member	3924 label Biography information for Yasmin Qureshi

155393

	registered interest
	date	11/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pregnancy Tests
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, when the Independent Panel on Hormone Pregnancy Tests will be set up; and what time frame he has set for that inquiry.
	tabling member constituency	Bolton South East
	tabling member printed	Yasmin Qureshi
	type	WrittenParliamentaryQuestion
	uin	214308
	answer	answer is ministerial correction date of answer 21/11/2014 answer text <p>Membership of the Group is currently being convened and will be finalised in December 2014. The time frame for the inquiry has yet to be finalised but the Panel is expected to review the evidence in the early months of 2015.</p><p> </p><p> </p><p> </p><p>Members of the Expert Working Group on Hormone Pregnancy Tests will be expected to declare any interests (financial or non-financial) in the pharmaceutical industry or in any other area that could affect their impartiality. All members’ interests will be carefully considered in advance and assessed when deciding on the appropriate level of participation in discussions.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 214307 question first answered 21/11/2014 14:26:47 answering member 4020 label Biography information for George Freeman
	tabling member	3924 label Biography information for Yasmin Qureshi

155394

	registered interest
	date	11/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pregnancy Tests
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what recent steps he has taken to ensure the impartiality and neutrality of members of the panel on hormone pregnancy tests.
	tabling member constituency	Bolton South East
	tabling member printed	Yasmin Qureshi
	type	WrittenParliamentaryQuestion
	uin	214307
	answer	answer is ministerial correction date of answer 21/11/2014 answer text <p>Membership of the Group is currently being convened and will be finalised in December 2014. The time frame for the inquiry has yet to be finalised but the Panel is expected to review the evidence in the early months of 2015.</p><p> </p><p> </p><p> </p><p>Members of the Expert Working Group on Hormone Pregnancy Tests will be expected to declare any interests (financial or non-financial) in the pharmaceutical industry or in any other area that could affect their impartiality. All members’ interests will be carefully considered in advance and assessed when deciding on the appropriate level of participation in discussions.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 214308 question first answered 21/11/2014 14:26:46 answering member 4020 label Biography information for George Freeman
	tabling member	3924 label Biography information for Yasmin Qureshi

155499

	registered interest
	date	11/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the benefits to the gathering of data on local cancer service standards of the National Cancer Peer Review programme.
	tabling member constituency	Bolton South East
	tabling member printed	Yasmin Qureshi
	type	WrittenParliamentaryQuestion
	uin	214306
	answer	answer is ministerial correction date of answer 21/11/2014 answer text <p>NHS England is currently reviewing the National Cancer Peer Review programme with a view to considering how its success might be extended into other new areas of specialised commissioning. This review will consider the benefits of the programme. Regardless of the outcome of this review, cancer peer review will continue to play a critical part of any broader peer review programme NHS England may look to introduce.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 21/11/2014 14:24:34 answering member 3918 label Biography information for Jane Ellison
	tabling member	3924 label Biography information for Yasmin Qureshi

156996

	registered interest
	date	20/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Dialysis Machines
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps NHS England has taken to ensure a safe transition of responsibility for dialysis commissioning to clinical commissioning groups from April 2015.
	tabling member constituency	Bolton South East
	tabling member printed	Yasmin Qureshi
	type	WrittenParliamentaryQuestion
	uin	215402
	answer	answer is ministerial correction date of answer 25/11/2014 answer text <p>NHS England has advised that it is in dialogue with key stakeholders about both the opportunities and challenges of transferring responsibility for renal services. The head of the Specialised Services Task Force in NHS England recently met stakeholders from renal service representative groups and heard their concerns directly. A new Task &amp; Finish group is being established by NHS England through the NHS Commissioning Assembly. This group will look specifically at what support clinical commissioning groups (CCGs) would require to be able to safely and effectively commission services devolved to them.</p><p> </p><p> </p><p> </p><p>The Prescribed Specialised Services Advisory Group (PSSAG) is a Department of Health appointed expert committee which was established in 2013 to provide the Secretary of State with advice and recommendations on specialised services. The PSSAG meets multiple times a year. The PSSAG met and formulated its recommendations on 30 September 2014, which concluded transferring commissioning responsibility for renal services. The Department intends to launch a public consultation before the end of 2014. The consultation will consider how to transfer commissioning responsibility and what would need to happen to ensure a smooth transition and maintain both service standards and patient safety.</p><p> </p><p> </p><p> </p><p>NHS England is committed to issuing commissioning guidance for the safe transfer of services from national NHS England responsibility to local CCG responsibility.</p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 215401 215404 question first answered 25/11/2014 17:14:11 answering member 3918 label Biography information for Jane Ellison
	tabling member	3924 label Biography information for Yasmin Qureshi